{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000058","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.107841+00:00","generated_at":"2026-06-03T02:27:19.025913+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings","bullets":["Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.","Closes Baltimore-Bayview Drug Substance and Rockville Drug Product manufacturing facilities.","Estimated charges of $18-21M primarily in H2 2024; expects annualized savings of ~$80M.","Operations concentrated at Winnipeg and Lansing; new Chief Science Officer role created.","Q1 2024 earnings to be reported May 1; also filed amendment to credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000058","json":"https://secwatch.observer/filing/0001367644-24-000058.json","markdown":"https://secwatch.observer/filing/0001367644-24-000058.md","text":"https://secwatch.observer/filing/0001367644-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/0001367644-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/ebs-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:27:19.025913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}